



Clinical Study of Acute Viral Hepatitis with Special Reference to Complementary and Alternative Medicine Induced Liver Injury

Bhaskar Thakuria, Navanita Das, MD Asif Reza, Joydeep Paul, Akash K. Holalkere

1. Medicine, Nalbari Medical College and Hospital, Nalbari, India

2. Pathology, Fakaruddin Ali Ahmed Medical College, Barpeta, India

3. Medicine, Gauhati Medical College and Hospital, Guwahati, India

4. Medicine, Gauhati Medical College and Hospital, Guwahati, India 5. Medicine, Gauhati Medical College and Hospital, Guwahati, India

Date of Submission: 16-03-2023

Date of Acceptance: 28-03-2023

ABSTRACT:

Background: Acute viral hepatitis continues to be a major public health problem in the world, especially in India. Complementary and alternative medicine (CAM) has gained much popularity and is preferentially used for various chronic diseases worldwide. Although CAM is generally thought to be safer than conventional drugs, many reports suggest hepatotoxicity and other adverse effects of herbal products. This study evaluates the clinical profile of the patients with acute viral hepatitis and its complications and clinical profile of patients of acute viral hepatitis taking "Complementary and Alternative Medicine".

Materials and Methods: A hospital based observational study was conducted on 130 patients who presented with serologically confirmed acute viral hepatitis with a history of intake of complementary and alternative medicine. Each patient underwent a detailed clinical and biochemical assessment. The data collected were tabulated and summarized as frequency and percentages.

Results: In our study most common clinical symptom in patients with Acute Viral Hepatitis were anorexia (79.23%) followed by yellowish discoloration of eyes (77.69%), nausea (75.38%), and malaise (73.07%). 33.8% patient had a history of taking Complementary and Alternative Medicine for the treatment of Acute Viral Hepatitis. 31.82% patients had Serum Bilirubin level was >20.1 mg/dl. Maximum number of patients (10 (22.73%)) with a history of CAM intake for AVH had an ALT level in the range of 1501-2000 IU/L. Hepatitis A was responsible for a majority of acute viral hepatitis with cholestasis being the most common complication. 9.09% of patients with CAM intake developed acute liver failure.

Conclusion: Complementary and alternative medicine intake is a popular method of treatment

for jaundice and commonly used in form of herbal medications. CAM use in acute viral hepatitis is associated with increased incidence of cholestasis and precipitating factor for acute liver failure.

Key Word: herbal medications, hepatotoxicity, jaundice, acute liver failure, complementary and alternative medicine, acute viral hepatitis

I. INTRODUCTION

Globally, acute viral hepatitis is a serious public health issue, particularly in emerging nations like India. One of the five viral agents—hepatitis A (HAV), hepatitis B (HBV), hepatitis C (HCV), HBV associated delta agent (HDV), and hepatitis E—causes nearly all episodes of acute viral hepatitis (HEV). With the exception of hepatitis B, which is a DNA virus, all of these human hepatitis viruses are RNA viruses. Acute hepatitis is a general diagnosis referring to any of a wide variety of conditions causing acute inflammation or injury to hepatocytes, resulting in elevation of liver biochemical lab tests¹.

Acute viral hepatitis can be defined clinically as an acute illness with a discrete onset of any sign or symptom consistent with acute viral hepatitis (e.g., fever, headache, malaise, anorexia, nausea, vomiting, diarrhoea, abdominal pain or dark urine). **AND** a) jaundice or elevated total bilirubin levels ≥ 3.0 mg/dL, **OR** b) elevated serum alanine aminotransferase (ALT) levels >200 IU/L, **AND** c) the absence of a more likely diagnosis. (Centres for Disease Control and Prevention USA 2019).

Hepatitis is classified as acute if it resolves in less than six months, and if abnormal findings last over six months, it is classified as chronic hepatitis². Natural childhood illnesses have declined as a result of advancements in sanitation, hygiene, and socioeconomic situations. As a result, there is a rise in the number of susceptible people



and a corresponding rise in the proportion of clinical disease, particularly acute viral hepatitis A. Hence, adult acute viral hepatitis A may be prevented to a great extent by hepatitis A immunisation.

Complementary and alternative medicine (CAM) has gained much popularity and is preferentially used for various chronic diseases, worldwide³. Compared to a single chemically-characterized drug, complementary and alternative medicine is a mixture of phytochemical constituents present in the herbal extracts⁴. In CAM/drug-induced liver injury, over or misdiagnosis is a common phenomenon⁵. The notion that these compounds are natural and safe and hence have no side effects has contributed to their popularity and widespread use. In a large cohort of patients with cirrhosis, Philips et al in 2019⁶ retrospectively studied complementary and alternative medicine-related health seeking behaviour and attempted to identify those who developed possible CAM-induced liver injury related acute on chronic liver failure. In a study of Drug-Induced Liver Injury at a Tertiary Hospital in India the most commonly implicated drugs were antitubercular therapy (ATT)(49%), antiepileptic drugs (12%), complementary and alternative medicine (CAM) in 10%, antiretroviral drugs (9%) and non-steroidal anti-inflammatory drugs (6%)⁷.

II. MATERIALS AND METHODS

This study was carried out in the Department of Medicine in a tertiary care hospital of Assam, for a period of one year from 1st June 2019 to 31st May 2020. This study was approved by the Institutional Ethics Committee of Gauhati Medical College and Hospital, Guwahati. The procedures followed were in accordance with the responsible committee's ethical standards based on the Good Clinical Practice guidelines.

Objectives: 1) To evaluate the clinical profile of the patients with Acute Viral Hepatitis attending the outpatient clinic and in-patient at Gauhati Medical College and Hospital.

2) To study the complications of Acute Viral Hepatitis in this group of patients.

3) To study the clinical profile of patients of Acute Viral Hepatitis taking "Complementary and alternative medicine."

Study Population: The study population included the patients who were serologically detected with acute viral hepatitis and a history of intake of Complementary and alternative medicine attending the OPD or were admitted in department of medicine of a tertiary care hospital in Assam, India.

Sample Size: 130 patients.

Inclusion criteria:

- 1) All patients with clinical and biochemical profile suggestive of acute hepatitis with at least one positive serological viral marker.
- 2) Patients with positive history of intake of complementary and alternative medicine including herbal medications.
- 3) Age of more than 12 years.
- 4) Patients willing to take part in the study.

Exclusion Criteria:

- 1) Intake of any Hepatotoxic allopathic medication (Drug induced Hepatitis)
- 2) Cholestatic jaundice of pregnancy.
- 3) Congestive Hepatopathy.
- 4) Cirrhosis of liver.
- 5) Past history of jaundice.

Procedure and Methodology:

Each patient underwent a complete clinical examination as well as a detailed history detailing their current symptoms and any potential risk factors for viral hepatitis. Complete blood count, liver function test, PT with INR, serum ammonia, serum amylase, serum lipase, and rapid malaria test were done. To rule out an extrahepatic source of cholestasis, ultrasonography of the entire abdomen was performed. The diagnosis was confirmed using serological viral markers. The presence of "Anti Hepatitis A virus IgM (IgM Anti HAV) by Enzyme linked immunosorbent assay (HAVAB M, Abbott Laboratories Chicago IL)" was used to confirm a diagnosis of hepatitis A. Acute hepatitis B was diagnosed by the presence of antibody against Hepatitis B core antigen (Anti HBcIgM) by Enzyme immune assay and a positive Hepatitis B surface Antigen (HBsAg) by immune assay. Hepatitis E was diagnosed by the presence of Anti Hepatitis E virus IgM (IgM Anti HAV) by enzyme immunoassay (Abbot Laboration III USA).

III. RESULTS

A total number of 130 cases were included in the study, who presented with features of acute viral hepatitis. A detailed history regarding presenting symptoms and possible risk factors for acquiring viral hepatitis was taken and a thorough clinical and biochemical examination was done.

The three most common clinical manifestations of Acute Viral Hepatitis were anorexia (79.23%), yellowish discoloration of the eyes (77.69%) and nausea (75.38%). Other common symptoms were headache, myalgia, arthralgia, itching, weight loss, and abdominal



discomfort. Rare presenting complaints included

photophobia and bleeding manifestations. (Table 1)

Features	No of Cases	Percentage
Anorexia	103	79.23%
Yellowish discolouration of eyes	101	77.69%
Nausea	98	75.38%
Malaise	95	73.07%
Fever	92	70.76%
Yellowish discolouration of urine	91	70.00%
Headache	80	61.53%
Vomiting	76	58.46%
Myalgia	73	56.15%
Itching	55	42.30%
Clay Coloured Stool	51	39.23%
Weight Loss	46	35.38%
Abdominal Discomfort	42	32.30%
Diarrhoea/Constipation	35	26.92%
Cough/Coryza	21	16.15%
Arthralgia	16	12.3%
Skin Rash	8	6.15%
Photophobia	3	2.30%
Bleeding Manifestations	2	1.53%

TABLE 1: Clinical Presentation in Acute Viral Hepatitis.

It was seen that out of 130 patients with acute viral hepatitis, 44(34%) patients had a history of CAM intake (figure 1).




FIGURE 1: Complementary and Alternative Medicine Intake In Acute Viral Hepatitis

In our study majority of the patients of AVH with CAM intake had serum bilirubin >20.1 mg/dl(31.82%)(Figure2).




FIGURE 2: Serum Bilirubin level of patients with CAM intake in AVH

Our study shows that in patients with CAM intake in AVH most of the patients 10(22.73%) had ALT level in the range of 1501-2000 IU/L(Table 2).



ALT in U/L (Range) Normal(21-72U/L)	Hepatitis A+CAM	Hepatitis B+CAM	Hepatitis E+CAM	Hepatitis A+E+CAM	Total No of Cases (%)
1-500	3	0	2	0	5(11.36%)
501-1000	5	2	2	0	9(20.45%)
1001-1500	6	1	1	0	8(18.19%)
1501-2000	8	0	2	0	10(22.73%)
2001-2500	3	0	1	1	5(11.37%)
2501-3000	2	0	0	0	2(4.55%)
3001-3500	0	0	0	1	1(2.27%)
3501-4000	0	0	1	0	1(2.27%)
4001-4500	0	0	1	0	1(2.27%)
4501-5000	1	0	0	0	1(2.27%)
5001-5500	1	0	0	0	1(2.27%)
Total	29	3	10	2	44(100%)

TABLE 2: ALT levels of patients with CAM intake in AVH

Most of the patients with Acute Viral Hepatitis with or without complications recovered fully. The patients who developed acute liver failure had a recovery rate of 33.33%(Table 3).

Categories	Total No of Patients	No Cholestasis Cases	of No Acute Liver Failure cases	No of Pancreatitis cases	of Acute cases
Hepatitis A	61	19(31.14%)	1(1.11%)	2(3.27%)	
Hepatitis Intake A+CAM	29	18(62.08%)	2(6.89%)	1(3.44%)	
Hepatitis B	5	0(0%)	1(12.50%)	0(0%)	
Hepatitis B+CAM Intake	3	1(33.33%)	0(0%)	0(0%)	
Hepatitis E	16	4(25%)	0(0%)	0(0%)	
Hepatitis E+CAM Intake	10	3(30%)	1(10%)	0(0%)	
Hepatitis A+E	4	3(75%)	0(0%)	0(0%)	



Hepatitis A+E+CAM Intake	2	1(50%)	1(50%)	0(0%)
Total	130	49	6	3

TABLE 3: CAM intake and complications in Acute Viral Hepatitis

IV. DISCUSSION

In our study, the most common clinical symptoms in patients with Acute Viral Hepatitis were anorexia (79.23%), yellowish discoloration of eyes (77.69%), nausea (75.38%), malaise (73.07%), fever (70.76%), yellowish discoloration of urine (70.0%). A few patients also reported headaches, arthralgia, itching, fever, weight loss, and abdominal discomfort. Whereas skin rash, photophobia, and bleeding diathesis were rarely found. Desai et al in 2020⁸ in their study found that the most common presenting symptom was yellowish discoloration of urine (84.2%) followed by yellowish discoloration of the sclera (81.2%) followed by anorexia (65.7%). In a study done by Shah et al in 2014⁹ the most common symptoms observed were jaundice(86.10%) followed by anorexia (76.50%), dark-coloured urine (73%), fever with chills (66.1%), and abdominalpain (36.3%).

In our study, it was found that 33.8% of patients had an intake of Complementary and Alternative Medicine for the treatment of Acute Viral Hepatitis which is found to be similar to a study by Leah M Ferrucci et al in 2010¹⁰ who found that (27.3%) of the patients used CAM therapies for their chronic liver disease. Patients in our study used CAM in the form of leaves of Phyllanthusniruri, aloe vera extract, and guava leaves which were found to be similar with regard to CAM intake formulation in the study of herbal medication-induced liver injury done by Philips et al in 2019¹¹.

In our study out of 130 patients, 49 patients (37.69%) with Acute Viral Hepatitis had features of cholestasis.

Similar results were obtained by Khuroo et al in 1994¹² (25% incidence of cholestatic hepatitis in Hepatitis E) and Perez et al in 1992¹³ (20% incidence of cholestatic hepatitis among Acute viral hepatitis). In our study, we found that out of 130 patients who presented with AVH 3(2.30%) patients had Pancreatitis, and all of them recovered. All the 3 cases were associated with HAV infection. Jain et al in 2007¹⁴ in their study of 124 patients with acute viral hepatitis found that 7(5.65%) patients had pancreatitis which recovered with conservative management. S.K Sarin et al in

1999¹⁵ in their study reported six cases of nonfulminant viral hepatitis complicated by acute pancreatitis, including the first documented case of hepatitis E virus (HEV) associated acute pancreatitis.

Maximum patients had Serum Bilirubin levels >20.1 mg/dl in 31.82 % of cases. In a study by Philips et al in 2019⁶ he found Mean+SD serum bilirubin in the range of 11.2 ± 6.7 mg/dl in patients with CAM-induced liver injury.

Our study showed a maximum number of patients 10(22.73%) with a history of CAM intake in patients of AVH had an ALT level in the range of 1501-2000 IU/L. In a case report by Hyo Jin Kim et al in 2015¹⁶ on a 55-year-old who had an intake of herbal extract, the patient's liver function test results showed significantly elevated aspartate aminotransferase (AST) (958 IU/L) and alanine aminotransferase (ALT) (1000 IU/L) levels.

In our study out of 44 cases of AVH 34(79%) had history of intake of CAM who developed features of cholestasis which can be compared to the study done by Philips et al in 2019¹¹ who showed that (67%) of the patients who took CAM in the form of Ayurvedic formulations developed cholestasis. Out of 44 patients who took CAM, 4(9.09%) patients developed acute liver failure. Acharya et al 1996¹⁷ in a study conducted in India, comprising 430 patients with acute liver failure, demonstrated that 4.5% (19/430) of the cases were related to drugs. Estes et al 2003¹⁸ showed in a series of 20 patients with acute liver failure referred to liver transplantation, (35%) of cases had no identified cause other than herbal supplement use.

V. CONCLUSIONS

Complementary and alternative medicine intake is a popular method of treatment for jaundice as seen in our study and is mostly used in the form of herbal medications. Our study shows that Complementary and alternative medicine use in acute viral hepatitis present with an increased incidence of cholestasis as well as a precipitating factor for acute liver failure consistent with increased serum bilirubin levels and serum ALT levels.



REFERENCES

- [1]. Cacciola I, Scoglio R, Alibrandi A, Squadrito G, Raimondo G; SIMG-Messina Hypertransaminasemia Study Group: Evaluation of liver enzyme levels and identification of asymptomatic liver disease patients in primary care. *Intern Emerg Med.* 2017, 12:181-186. 10.1007/s11739-016-1535-2. Epub 2016 Sep 19.
- [2]. Agrawal, S., Dhiman, R. K., & Limdi, J. K. (2016): Evaluation of abnormal liver function tests. 92:223-234. 10.1136/pmj.79.932.307
- [3]. Vickers, A., 2000: Complementary medicine. *BMJ.* 321:683-686. 10.1136/bmj.321.7262.683
- [4]. Gupta, N.K. and Lewis, J.H., 2008: The use of potentially hepatotoxic drugs in patients with liver disease. *Alimentary pharmacology.* 28:1021-1041. 10.1111/j.1365-2036.2008.03822.x
- [5]. Dalton HR, Fellows HJ, Stableforth W, et al.: The role of hepatitis E virus testing in drug-induced liver injury. *Aliment Pharmacol Ther.* 2007, 15:1429-35. 10.1128/CMR.00057-13
- [6]. Philips CA, Paramaguru R, Augustine P, et al.: A Single-Center Experience on Outcomes of Complementary and Alternative Medicine Use Among Patients With Cirrhosis. *Hepatol Commun.* 2019, 12:1001-1012. 10.1002/hep4.1355
- [7]. Rathi C, Pipaliya N, Patel R, et al.: Drug Induced Liver Injury at a Tertiary Hospital in India: Etiology, Clinical Features and Predictors of Mortality. *Ann Hepatol.* 2017, 16:442-450. 10.5604/16652681.1235488.
- [8]. Desai HD, Ansari AAZ, Makwana D, et al.: Clinical-biochemical profile and etiology of acute viral hepatitis in hospitalized young adults at tertiary care center. *J Family Med Prim Care.* 2020, 28:247-252. 10.4103/jfmpc.jfmpc_727_19
- [9]. Shah N, Kadla S, Shafi P, et al.: Clinico-Serological profile of Acute Sporadic Viral Hepatitis in Kashmiri Adults: Hospital based Prospective Study. *Journal of Medical Science and Clinical Research.* 2014, 2:311926.
- [10]. Leah M. Ferrucci, Beth P. Bell, Kathy B. Dhotre, et al.: Complementary and Alternative Medicine Use in Chronic Liver Disease Patients; *J Clin Gastroenterol.* 44: pp 45. 10.1097/MCG.0b013e3181b766ed
- [11]. Philips CA, Augustine P, Rajesh S, et al.: Complementary and Alternative Medicine-related Drug-induced Liver Injury in Asia. *J Clin Transl Hepatol.* 2019, 28:263-274. 10.14218/JCTH.2019.00024
- [12]. Khuroo MS, Rustgi VK, Dawson GJ, et al.: Spectrum of hepatitis E virus infection in India. *J Med Virol.* 1994, 43:281-6. 10.1002/jmv.1890430316
- [13]. Perez CA, Oviedo JJ; Gonzaler ML (1992); The evaluation of acute viral hepatitis seen in regional hospital; *Acta Gastroenterol Latino americana.* 22:389-42.
- [14]. Jain P, Nijhawan S, Rai RR, et al.: Acute pancreatitis in acute viral hepatitis. *World J Gastroenterol.* 2007, 21:5741-4. 10.3748/wjg.v13.i43.5741
- [15]. S. K. Sarin, A. Mishra, S. Saigal and R. Gupta (1999): —Acute pancreatitis associated with viral hepatitis: a report of six cases with review of literature. *l. American Journal of Gastroenterology,* vol. 94, no. 8. pp.:2292-2295. 10.1016/S0002-9270(99)00374-3
- [16]. Hyo Jin Kim; Hyunah Kim, Ji Hyune Ahn, and Hyoun Ju Suk (2015); Liver Injury Induced by Herbal Extracts Containing Mistletoe and Kudzu; *The Journal of Alternative and Complementary Medicine.* pp.180-185. 10.1089/acm.2014.0228
- [17]. Acharya SK, Dasarathy S, Kumer TL, et al.: Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. *Hepatology.* 1996, 23:1448-55. 10.1002/hep.510230622
- [18]. d Estes, J., Stolpman, D. and Olyaei, A., 2003: High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. *Archives of Surgery.* 138:852-858. 10.1001/archsurg.138.8.852